In a major boost for Biocon, the USFDA has approved their application for biosimilar, Pegfilgrastim. Kiran Mazumdar Shaw, CMD of Biocon shared her views.
“Pegfilgrastim is a $4 billion dollar in the US and Europe and a huge milestone for Biocon because we are the first to be approved as a biosimilar,” she said.
“We will be able to enter the market very soon, FY19 for sure,” she added.
“It is a very large opportunity and Mylan is feeling confident that being the first mover, it will have a good advantage and we will make every effort to garner maximum market share,” said Shaw.